GigaGen
  • Our Company
    • Team
    • News
  • Our Science
    • Surge and Magnify Technologies
    • Publications, Scientific Posters & Presentations
  • Pipeline
    • Oncology
    • Recombinant Polyclonals
  • Collaborations
  • Careers
  • Contact
  • Menu Menu

Drug Target Review: Intravenous immunoglobulins, hyperimmunes and pandemic viruses

News, Uncategorized

David Johnson of GigaGen discusses how recombinant forms of intravenous immunoglobulins (IVIG) could overtake current IVIG therapies and be used in the treatment of COVID-19.

Read the full story.

05/04/2020/by jkeller
Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on WhatsApp
  • Share on LinkedIn
  • Share by Mail
© Copyright 2020 GigaGen. All Rights Reserved.
  • Twitter
  • LinkedIn
Scroll to top